Orimeten en es it fr

Orimeten Brand names, Orimeten Analogs

Orimeten Brand Names Mixture

  • No information avaliable

Orimeten Chemical_Formula


Orimeten RX_link


Orimeten fda sheet

Orimeten FDA

Orimeten msds (material safety sheet)

Orimeten Synthesis Reference

Hoffmann, Urech, U.S. pat. 2,848,455 (1958 to Ciba)

Orimeten Molecular Weight

232.278 g/mol

Orimeten Melting Point

149-150 oC

Orimeten H2O Solubility

Practically insoluble in water

Orimeten State


Orimeten LogP


Orimeten Dosage Forms

Tablet (250 mg)

Orimeten Indication

For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.

Orimeten Pharmacology

Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.

Orimeten Absorption

Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.

Orimeten side effects and Toxicity

Oral LD50s (mg/kg): rats, 1800; dogs, >100. Intravenous LD50s (mg/kg): rats, 156; dogs, >100. Symptoms of overdose include respiratory depression, hypoventilation, hypotension, hypovolemic shock due to dehydration, somnolence, lethargy, coma, ataxia, dizziness, fatigue, nausea, and vomiting.

Orimeten Patient Information

Orimeten Organisms Affected

Humans and other mammals